110 related articles for article (PubMed ID: 17646260)
1. Tumor necrosis factor family receptors regulating bone turnover: new observations in osteoblastic and osteoclastic cell lines.
Robinson LJ; Borysenko CW; Blair HC
Ann N Y Acad Sci; 2007 Nov; 1116():432-43. PubMed ID: 17646260
[TBL] [Abstract][Full Text] [Related]
2. Death receptor-3 mediates apoptosis in human osteoblasts under narrowly regulated conditions.
Borysenko CW; García-Palacios V; Griswold RD; Li Y; Iyer AK; Yaroslavskiy BB; Sharrow AC; Blair HC
J Cell Physiol; 2006 Dec; 209(3):1021-8. PubMed ID: 16986165
[TBL] [Abstract][Full Text] [Related]
3. Regulatory roles and molecular signaling of TNF family members in osteoclasts.
Feng X
Gene; 2005 Apr; 350(1):1-13. PubMed ID: 15777737
[TBL] [Abstract][Full Text] [Related]
4. Alteration of activity and survival of osteoblasts obtained from human periodontitis patients: role of TRAIL.
Mori G; Brunetti G; Colucci S; Ciccolella F; Coricciati M; Pignataro P; Oranger A; Ballini A; Farronato D; Mastrangelo F; Tetè S; Grassi FR; Grano M
J Biol Regul Homeost Agents; 2007; 21(3-4):105-14. PubMed ID: 18261262
[TBL] [Abstract][Full Text] [Related]
5. TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation from monocyte/macrophage lineage precursor cells.
Yen ML; Tsai HF; Wu YY; Hwa HL; Lee BH; Hsu PN
Mol Immunol; 2008 Apr; 45(8):2205-13. PubMed ID: 18206242
[TBL] [Abstract][Full Text] [Related]
6. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio.
Seriwatanachai D; Thongchote K; Charoenphandhu N; Pandaranandaka J; Tudpor K; Teerapornpuntakit J; Suthiphongchai T; Krishnamra N
Bone; 2008 Mar; 42(3):535-46. PubMed ID: 18166509
[TBL] [Abstract][Full Text] [Related]
7. Osteoclast-osteoblast communication.
Matsuo K; Irie N
Arch Biochem Biophys; 2008 May; 473(2):201-9. PubMed ID: 18406338
[TBL] [Abstract][Full Text] [Related]
8. Physiopathological basis of bone turnover.
Masi L; Brandi ML
Q J Nucl Med; 2001 Mar; 45(1):2-6. PubMed ID: 11456372
[TBL] [Abstract][Full Text] [Related]
9. Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis.
Roux S; Lambert-Comeau P; Saint-Pierre C; Lépine M; Sawan B; Parent JL
Biochem Biophys Res Commun; 2005 Jul; 333(1):42-50. PubMed ID: 15936719
[TBL] [Abstract][Full Text] [Related]
10. Expression and function of TNF-family proteins and receptors in human osteoblasts.
Bu R; Borysenko CW; Li Y; Cao L; Sabokbar A; Blair HC
Bone; 2003 Nov; 33(5):760-70. PubMed ID: 14623051
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer cells induce osteoblast apoptosis: a possible contributor to bone degradation.
Mastro AM; Gay CV; Welch DR; Donahue HJ; Jewell J; Mercer R; DiGirolamo D; Chislock EM; Guttridge K
J Cell Biochem; 2004 Feb; 91(2):265-76. PubMed ID: 14743387
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway.
Yamashita M; Otsuka F; Mukai T; Otani H; Inagaki K; Miyoshi T; Goto J; Yamamura M; Makino H
J Endocrinol; 2008 Mar; 196(3):601-13. PubMed ID: 18310456
[TBL] [Abstract][Full Text] [Related]
13. Osteoblast apoptosis and bone turnover.
Hock JM; Krishnan V; Onyia JE; Bidwell JP; Milas J; Stanislaus D
J Bone Miner Res; 2001 Jun; 16(6):975-84. PubMed ID: 11393794
[TBL] [Abstract][Full Text] [Related]
14. Direct and indirect estrogen actions on osteoblasts and osteoclasts.
Zallone A
Ann N Y Acad Sci; 2006 Apr; 1068():173-9. PubMed ID: 16831916
[TBL] [Abstract][Full Text] [Related]
15. Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.
Gasparian ME; Chernyak BV; Dolgikh DA; Yagolovich AV; Popova EN; Sycheva AM; Moshkovskii SA; Kirpichnikov MP
Apoptosis; 2009 Jun; 14(6):778-87. PubMed ID: 19412666
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL).
Zauli G; Rimondi E; Celeghini C; Milani D; Secchiero P
J Cell Physiol; 2010 Feb; 222(2):357-64. PubMed ID: 19877156
[TBL] [Abstract][Full Text] [Related]
17. Osteoclast culture and resorption assays.
Bradley EW; Oursler MJ
Methods Mol Biol; 2008; 455():19-35. PubMed ID: 18463808
[TBL] [Abstract][Full Text] [Related]
18. Regulation of apoptosis in osteoclasts and osteoblastic cells.
Xing L; Boyce BF
Biochem Biophys Res Commun; 2005 Mar; 328(3):709-20. PubMed ID: 15694405
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway.
Chamoux E; Houde N; L'Eriger K; Roux S
J Cell Physiol; 2008 Aug; 216(2):536-42. PubMed ID: 18338379
[TBL] [Abstract][Full Text] [Related]
20. High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas.
Sanlioglu AD; Dirice E; Elpek O; Korcum AF; Balci MK; Omer A; Griffith TS; Sanlioglu S
Pancreas; 2008 May; 36(4):385-93. PubMed ID: 18437085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
